Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Distinct requirements for Ras oncogenesis in human versus mouse cells.

Nesrin M Hamad1, Joel H Elconin, Antoine E Karnoub

  • 1Department of Pharmacology, Division of Neurology, Duke University Medical Center, Durham North Carolina 27710, USA.

Genes & Development
|August 17, 2002
PubMed
Summary

Oncogenic Ras transforms human cells via the RalGEF pathway, unlike in mice. This finding suggests RalGEF is a potential new target for anti-cancer therapies, differing from current understanding.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

Cancer discovery·2026
Same author

Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports·2026
Same author

Advances in RAS Therapeutics for Pancreatic Cancer.

The New England journal of medicine·2026
Same author

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer.

bioRxiv : the preprint server for biology·2026
Same author

KRAS Signaling Inhibition Induces a Targetable Metabolic Dependency on Lipophagy-Dependent Fatty Acid Oxidation in Pancreatic Cancer.

Cancer research·2026
Same author

Editorial Expression of Concern: Creation of human tumour cells with defined genetic elements.

Nature·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Oncogenic Ras proteins are key drivers in human cancers.
  • Ras signaling pathways, including Raf, PI3-kinase, and RalGEF, are implicated in cell transformation.
  • Observed differences in Ras-driven tumors between humans and mice suggest distinct transformation mechanisms.

Purpose of the Study:

  • To investigate the specific Ras effector pathways responsible for cell transformation in human cells.
  • To elucidate the differential roles of Raf, PI3-kinase, and RalGEF in Ras-mediated transformation.
  • To identify potential new therapeutic targets for Ras-driven cancers.

Main Methods:

  • Utilized oncogenic Ras mutants engineered to selectively activate individual effector pathways (Raf, PI3-kinase, RalGEF).

Related Experiment Videos

  • Employed constitutively active forms of effector proteins to confirm pathway sufficiency.
  • Assessed the transforming capacity of Ras mutants and activated effectors in human cell models.

    • Main Results:

    • The RalGEF pathway, independently, was sufficient for Ras-mediated cell transformation in human cells.
    • Activation of the Raf or PI3-kinase pathways alone was insufficient for transformation in this context.
    • This contrasts with murine models where Raf is often the dominant transforming pathway.

    Conclusions:

    • Ras-driven cell transformation mechanisms differ significantly between human and murine cells.
    • The RalGEF pathway plays a critical, previously underestimated role in human Ras transformation.
    • Targeting the RalGEF pathway presents a novel therapeutic strategy for human cancers driven by oncogenic Ras.